Developing tamibarotene for patients with
RARA gene overexpression in hematological malignancies

At Syros Pharmaceuticals, we're on a mission to offer hope to patients with blood disorders through biologically targeted solutions. We are developing tamibarotene, an oral selective RARα agonist in late-stage clinical development, for higher-risk myelodysplastic syndrome patients with RARA gene overexpression. When RARA is overexpressed, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematologic malignancies. However, when oral tamibarotene is administered, tamibarotene has been observed to bind to RARα, allowing for the restoration of gene expression and myeloid differentiation. With approximately 50% of MDS patients exhibiting RARA overexpression, tamibarotene has the potential to offer a targeted treatment option. Join us on this journey as we work to pave the way for a brighter future for patients with hematologic malignancies.